1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-
| Title | Journal |
|---|---|
| Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease. | Neurobiology of disease 20161201 |
| Getting personal: Endogenous adenosine receptor signaling in lymphoblastoid cell lines. | Biochemical pharmacology 20160901 |
| Adenosine A2A receptor as a drug discovery target. | Journal of medicinal chemistry 20140508 |
| 1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. | Bioorganic & medicinal chemistry 20131201 |
| Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease. | Journal of clinical pharmacology 20121001 |
| Design and synthesis of 8-substituted benzamido-phenylxanthine derivatives as MAO-B inhibitors. | Bioorganic & medicinal chemistry letters 20120215 |
| Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. | Parkinsonism & related disorders 20120201 |
| Istradefylline for the treatment of Parkinson's disease. | Expert opinion on pharmacotherapy 20120101 |
| Functional changes in postsynaptic adenosine A(2A) receptors during early stages of a rat model of Huntington disease. | Experimental neurology 20111101 |
| An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats. | Fundamental & clinical pharmacology 20111001 |
| Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones. | European journal of medicinal chemistry 20110901 |
| An update on adenosine A2A receptors as drug target in Parkinson's disease. | CNS & neurological disorders drug targets 20110901 |
| Biophysical mapping of the adenosine A2A receptor. | Journal of medicinal chemistry 20110714 |
| Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin. | Journal of clinical pharmacology 20110501 |
| Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. | Expert opinion on drug metabolism & toxicology 20110401 |
| International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. | Pharmacological reviews 20110301 |
| Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist. | Journal of medicinal chemistry 20110210 |
| Population pharmacokinetic analysis of istradefylline in healthy subjects and in patients with Parkinson's disease. | Journal of clinical pharmacology 20110101 |
| In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease. | Journal of medicinal chemistry 20101125 |
| An efficient route to xanthine based A(2A) adenosine receptor antagonists and functional derivatives. | Organic & biomolecular chemistry 20100921 |
| Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists. | Bioorganic & medicinal chemistry letters 20100901 |
| Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. | Movement disorders : official journal of the Movement Disorder Society 20100730 |
| A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. | Parkinsonism & related disorders 20100701 |
| Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. | Parkinsonism & related disorders 20100101 |
| Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. | Journal of neurochemistry 20100101 |
| Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin. | Journal of clinical pharmacology 20091201 |
| Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamide. | Neuroscience 20090929 |
| Differential actions of adenosine A1 and A2A antagonists on the effort-related effects of dopamine D2 antagonism. | Behavioural brain research 20090719 |
| Adenosine, adenosine A 2A antagonists, and Parkinson's disease. | Parkinsonism & related disorders 20090701 |
| Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090601 |
| Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides. | Bioorganic & medicinal chemistry letters 20090515 |
| Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. | Journal of medicinal chemistry 20090108 |
| Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. | Movement disorders : official journal of the Movement Disorder Society 20081115 |
| The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates. | Psychopharmacology 20081001 |
| Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. | Bioorganic & medicinal chemistry 20080915 |
| A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin. | Journal of clinical pharmacology 20080901 |
| Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. | Synapse (New York, N.Y.) 20080901 |
| A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. | Neurology 20080603 |
| Inflammation in Parkinson's disease: an update. | Current opinion in investigational drugs (London, England : 2000) 20080501 |
| Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism. | Frontiers in bioscience : a journal and virtual library 20080501 |
| Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. | Experimental neurology 20080401 |
| A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20080319 |
| Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. | Annals of neurology 20080301 |
| Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). | Annals of neurology 20080301 |
| Parkinson's Disease and Related Disorders--XVIIth WFN world congress. | IDrugs : the investigational drugs journal 20080301 |
| Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? | Annals of neurology 20080301 |
| Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. | Journal of medicinal chemistry 20080214 |
| Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol. | Neuropharmacology 20080101 |
| The effect of caffeine to increase reaction time in the rat during a test of attention is mediated through antagonism of adenosine A2A receptors. | Behavioural brain research 20071211 |
| Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands. | Bioorganic & medicinal chemistry 20071115 |
| N9-benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: synthesis and structure-activity relationships at adenosine A1 and A2A receptors. | Bioorganic & medicinal chemistry 20070715 |
| The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats. | Neurobiology of learning and memory 20070701 |
| Amphetamine and the adenosine A(2A) antagonist KW-6002 enhance the effects of conditional temporal probability of a stimulus in rats. | Behavioral neuroscience 20070601 |
| Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. | Naunyn-Schmiedeberg's archives of pharmacology 20070401 |
| 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. | Journal of medicinal chemistry 20070222 |
| Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20061227 |
| Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease. | Journal of the neurological sciences 20061025 |
| Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for neurodegenerative diseases. | Expert opinion on investigational drugs 20060801 |
| Regulation of phosphorylation of the GluR1 AMPA receptor by dopamine D2 receptors. | Journal of neurochemistry 20060101 |
| The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat. | Psychopharmacology 20060101 |
| Effects of the A 2A adenosine receptor antagonist KW6002 in the nucleus accumbens in vitro and in vivo. | Pharmacology, biochemistry, and behavior 20060101 |
| New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. | Life sciences 20051112 |
| Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20051109 |
| 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. | Journal of medicinal chemistry 20051103 |
| Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. | Experimental neurology 20050701 |
| Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. | Expert opinion on investigational drugs 20050601 |
| Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. | Pharmacology & therapeutics 20050301 |
| KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. | Neuropharmacology 20050301 |
| Other pharmacological treatments for motor complications and dyskinesias. | Movement disorders : official journal of the Movement Disorder Society 20050101 |
| Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. | Drugs & aging 20050101 |
| Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. | The Journal of organic chemistry 20040514 |
| Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. | Neuroscience 20040101 |
| A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. | Neurology 20031209 |
| A2A receptors in neuroprotection of dopaminergic neurons. | Neurology 20031209 |
| Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. | Neurology 20031209 |
| Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. | Neurology 20031209 |
| Adenosine A2A receptors and depression. | Neurology 20031209 |
| Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. | Neurology 20031209 |
| Translating A2A antagonist KW6002 from animal models to parkinsonian patients. | Neurology 20031209 |
| A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. | Experimental neurology 20031101 |
| Nondopaminergic symptomatic therapies for Parkinson's disease: turn on or turn off? | Neurology 20030812 |
| Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. | Neurology 20030812 |
| Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. | Neurology 20030812 |
| Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. | Glia 20030801 |
| Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. | Bioorganic & medicinal chemistry 20030403 |
| Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. | Journal of neurochemistry 20030301 |
| Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain. | Brain research 20021025 |
| [The treatment of Parkinson's disease--adenosine A2A receptor antagonists]. | Nihon rinsho. Japanese journal of clinical medicine 20020101 |
| Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. | Journal of neurochemistry 20020101 |
| Evaluation of [4-O-methyl-(11)C]KW-6002 as a potential PET ligand for mapping central adenosine A(2A) receptors in rats. | Synapse (New York, N.Y.) 20011201 |
| Solubilisation and immunoprecipitation of rat striatal adenosine A(2A) receptors. | European journal of pharmacology 20011116 |
| Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's disease. | Neurotoxicity research 20011101 |
| Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. | British journal of pharmacology 20010901 |
| Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20010515 |
| KW-6002 (Kyowa Hakko Kogyo). | Current opinion in investigational drugs (London, England : 2000) 20010501 |
| Selective adenosine A2A receptor antagonists. | Farmaco (Societa chimica italiana : 1989) 20010101 |
| Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. | Experimental neurology 20000401 |
| Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. | Psychopharmacology 19991101 |